Briefing
Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia (MURANO)
Phase 3 randomized venetoclax-rituximab vs bendamustine-rituximab in relapsed/refractory CLL, establishing fixed-duration Ven-R and high rates of undetectable MRD that were further analyzed in Kater et al., J Clin Oncol 2019 (PMID 30523712). Level 2.
- Design: paper
- Assay: MRD as a key secondary/exploratory depth-of-response measure